Subgroup ngioplasty for this study to help decision making by the interventionists. Of prasugrel in TRITON TIMI 38, a big e multicenter study randomized 13 608 ACS with moderate to high risk patients with P2X Receptor ACS and 60 mg/10 mg prasugrel or clopidogrel 300 mg/10 mg evaluated once the coronary anatomy was determined by angiography. Ticagrelor Plato was in a multicenter study of 18.624 patients with ACS randomized 180 mg/90 mg bd ticagrelor versus clopidogrel 300 mg/75 mg evaluated. 19.6% of patients in the clopidogrel arm and 13.7% ticagrelor clopidogrel arm had given 675 mg to 600 within 24 hours before or after randomization. 600 mg of clopidogrel showed a profit of more than 300 mg total of 28.307 patients, meta-analysis of patients undergoing PCI or shows a mg 0.74 for 600th This is comparable with other meta-analysis, the recommended risk reduction of 24% of MACE in ACS. Prasugrel in TRITONTIMI 38 showed a reduction in MACE at 30 days and 15 months, mainly due to a reduction of type 1 and 4 myocardial infarction. Ticagrelor Plato has not demonstrated a statistically significant reduction in MACE at 30 days, may be hampered by many patients with early exposure to clopidogrel. A net weight reduction is seen at 1 year, both between and within the subgroup under invasive treatment. 1.2. Overall mortality Overall mortality t t was analyzed in order to avoid the impact of different definitions of biochemical and heart attack. In 28.333 patients, has 600 mg of clopidogrel no clear statistical significance, but was seen to benefit from a trend. Died after 12 months was described by Choi et al. and not by Mangiacapra et al. and therefore not meta-analysis. TRITON TIMI 38 have shown that prasugrel was no difference in death after 15 months. PLATO showed reduced overall mortality ticagrelor t. 1.3. H Haemorrhagic bleeding rates reported are variable.
We focused on strictly defined TIMI major bleeding rates of difficulties with the definitions of the study to avoid, are not comparable blood flow and varying ratio Ltnissen of GUSTO bleeding. Table 2 summarizes the available data of the blood flow of 600 mg clopidogrel trial, TRITON and Plato. Bleeding was no statistically significant differences between the two dosing strategies for clopidogrel. Both prasugrel and ticagrelor increased Ht fa Is not in TIMI major bleeding, and 600 mg of TGF-beta clopidogrel significantly. 1.4. Analysis of cooperation Ts and better estimates Sch About the impact of the three strategies results Figure 2 shows the current page three strategies to c Under the traditional strategy of loading 300 mg. The estimates point switch Risk reduction of the 3 new strategies Similar. Bleedingcomplications seem significant gr It at 600 mg of clopidogrel, but h Are very convenient for new officers. In collaboration additionally t USEFUL strategies are very different. Clopidogrel 600 mg 0.32 adds strategy beyond the traditional strategy of loading. It is typical to stop clopidogrel at 1 year and therefore no co t is further coated Ftigt. Both prasugrel and ticagrelor add co Ts more important than the 665 or Figure 2C. The analysis assumes that these agents also arrested in a year: if the administration continues to expand, the difference in co-t on. The authors of this manuscript hav.
Other articles you might like;
- erismodegib was largely correlated with inflammation and bone resorption
- Lapatinib is not lost PARP3 in human cells
- EX 527 SEN0014196 is probably well tolerated In contrast